Deloitte, a global accounting and consulting firm, released its 2024 Technology Fast 500 list. The ranking features the fastest-growing technology and life sciences companies in North America. The 30th annual list featured 34 companies from the Boston area. Last year’s list featured 37 companies.
Companies on the list were chosen based on their fiscal year revenue growth between 2020 and 2023 and ranked based on their percentage growth rate. Overall, the companies featured achieved revenue growth ranging from 201 percent to 153,625 percent over this three-year period. The technology sector, as well as the media, telecommunications, life sciences, fintech and energy tech industries, are represented on the list.
“To see 34 Boston-area companies achieve the revenue growth required to land on this list is inspiring,” Denise Diehl, managing director of Deloitte & Touche and Deloitte’s New England emerging growth company practice leader, said in a statement. “New England has a fantastic infrastructure to support this growth, as there is a network of talent, investors and academic research centers that lean into the innovation and perseverance that helps to foster success.”
Read on for details on the top five Boston-area tech companies included in this year’s Deloitte ranking and be sure to check out the full list.
Top Boston Tech Companies on Deloitte’s 2024 Technology Fast 500
- Circle
- Uwill
- Foghorn Therapeutics
- Mersana Therapeutics
- 1upHealth
Ranked #43, 3,527% Growth
1upHealth is an IT company operating within the healthcare sector. It provides a health data interoperability platform that makes it easier for Medicaid agencies, digital health organizations and more to acquire, manage, share and compute data. The company launched a new patient-facing solution last month to connect individuals to their health information. 1upHealth’s cloud-based platform has covered more than 270 million patient lives to date.
Ranked #36, 4,351% Growth
Biopharma company Mersana Therapeutics develops antibody-drug conjugates intended to treat cancers. Its cytotoxic and immunostimulatory antibody-drug platforms have generated a pipeline of product candidates that have advanced into clinical trials. Its products include a dolasynthen candidate targeting breast cancer. Mersana announced it earned $12.6 million in collaboration revenue during Q3 2024.
Ranked #24, 7,843% Growth
Foghorn Therapeutics is working to develop medicines targeting genetically determined dependencies within the chromatin regulatory system. The company announced $110 million in stock proceeds back in May. As it creates product candidates in the oncology sector, Foghorn’s platform provides it with insights that enable it to identify, validate and drug targets within the chromatin regulatory system.
Ranked #18, 8,722% Growth
Mental health and wellness company Uwill provides college students with a student and therapist matching platform. The company works to offer a cost-effective solution that grants immediate access to appointments with a licensed counselor. Students can specify their preferences and receive teletherapy, crisis support, prescription medication management services and more. Uwill acquired Californian mental health company Virtual Care Group over the summer.
Ranked #17, 9,294% Growth
Circle offers a fintech platform that provides USDC and Web3 services. The company created USDC, a digital currency backed by the U.S. dollar, with the goal of raising global economic prosperity through the frictionless exchange of value. It recently launched a liquidity management solution in partnership with fintech company Thunes. Alongside stablecoins and currency conversion tools, the company provides programmable wallets and a smart contract management platform.
